CHA Vaccine Research Institute (KOSDAQ:261780)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,800.00
+85.00 (3.13%)
At close: Jan 23, 2026
-7.59%
Market Cap76.30B
Revenue (ttm)158.62M -57.2%
Net Income-14.25B
EPS-531.06
Shares Out26.87M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,289
Average Volume102,096
Open2,740.00
Previous Close2,715.00
Day's Range2,690.00 - 2,800.00
52-Week Range2,360.00 - 3,660.00
Beta0.66
RSI60.30
Earnings Daten/a

About KOSDAQ:261780

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products targeting infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and can... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 261780
Full Company Profile

Financial Performance

In 2024, KOSDAQ:261780's revenue was 370.66 million, an increase of 26.02% compared to the previous year's 294.12 million. Losses were -10.14 billion, 479.5% more than in 2023.

Financial Statements